Vivani Medical Inc Dossier - Source-backed chat

Vivani Medical Inc

VANINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.52

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.24Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $111.9M

Enterprise Value $92M

Shares Outstanding 87.3M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vivani Medical, Inc. (NASDAQ: VANI) represents a high-potential, clinical-stage biopharmaceutical opportunity leveraging its proprietary NanoPortal™ subdermal implant technology to address the massive and rapidly growing obesity market. By developing miniature, ultra-long-acting implants like NPM-139 (semaglutide), Vivani directly targets the critical real-world challenges of poor medication adherence and gastrointestinal tolerability associated with daily or weekly oral and injectable GLP-1 therapies. With a solid cash runway extending into mid-2027, a successful first-in-human proof-of-concept via the LIBERATE-1 trial, and the imminent mid-2026 initiation of the SLIM-1 Phase 1 trial in Australia, Vivani is well-positioned to achieve major clinical de-risking milestones over the next 12 months.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.50

Mean target$3.83

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.1520%

The SLIM-1 trial experiences clinical or regulatory delays in Australia, pushing top-line data readouts into 2027. Pharmacokinetic data reveals inconsistent drug release or local tolerability issues with the semaglutide implant, undermining the NanoPortal platform's viability. Capital markets tighten, and the lack of a strategic partner forces highly dilutive equity raises as the cash runway approaches its limit in early 2027. Cortigent's separation remains stalled, continuing to drain administrative resources.

Base CaseCentral scenario

$3.5050%

Vivani successfully initiates the SLIM-1 Phase 1 trial in mid-2026 and reports positive top-line safety and pharmacokinetic data by year-end. The cash runway remains secure through the first half of 2027, supported by disciplined R&D spending and structured insider purchases by major shareholder Gregg Williams. The company progresses toward a pre-IND meeting with the FDA and prepares for a Phase 2 study in 2027, while continuing to evaluate strategic separation options for Cortigent. Valuation aligns with consensus analyst expectations.

Bull CaseUpside scenario

$4.0030%

The SLIM-1 Phase 1 trial of NPM-139 delivers outstanding safety, tolerability, and smooth pharmacokinetic release profiles by the end of 2026, validating the NanoPortal platform for semaglutide. Vivani successfully partners with a major pharmaceutical company for global co-development, securing substantial upfront non-dilutive funding. Concurrently, the successful spin-off or IPO of its neurostimulation subsidiary, Cortigent, unlocks significant hidden balance-sheet value and eliminates legacy overhead, driving the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary NanoPortal™ platform technology offers a unique, reversible, ultra-long-acting subdermal delivery system that guarantees medication adherence for 6 months or longer.
Lead candidate NPM-139 targets the multi-billion-dollar obesity market, addressing the >50% real-world discontinuation rate of weekly GLP-1 injectables.
Successful completion of the first-in-human LIBERATE-1 trial (NPM-115 exenatide implant) provides strong clinical proof-of-concept for the NanoPortal platform's safety and tolerability.
Strong financial backing and alignment of interest demonstrated by continuous, multi-million-dollar open-market and private stock purchases by director and major shareholder Gregg Williams.
Strategic flexibility to unlock value from the neurostimulation division through the planned separation of subsidiary Cortigent.

Key Investment Risks

Clinical-stage execution risk: The company's valuation is heavily dependent on the upcoming SLIM-1 Phase 1 trial results for NPM-139.
Dilution risk: As a pre-revenue biotechnology firm, Vivani will require substantial additional capital to fund late-stage clinical trials and commercialization beyond its mid-2027 cash runway.
Intense market competition: The obesity space is dominated by well-capitalized pharmaceutical giants (e.g., Novo Nordisk, Eli Lilly) developing their own long-acting and oral formulations.
Regulatory hurdles: Subdermal drug-device combination products face complex, multi-disciplinary review pathways with the FDA and international regulators.

Thesis Invalidation Triggers

Failure to initiate the SLIM-1 Phase 1 clinical trial by the end of Q3 2026.
Unfavorable safety signals, severe local tissue reactions, or failure to achieve steady-state therapeutic drug levels in the SLIM-1 trial.
Inability to secure additional financing or a strategic partnership before the end of the first half of 2027.
A definitive termination or failure of the Cortigent separation plans without alternative value-unlocking mechanisms.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.